{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:21:02Z","timestamp":1740144062884,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s40261-020-00945-z","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T11:07:44Z","timestamp":1594292864000},"page":"873-881","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Signals of Adverse Drug Reactions of Paliperidone Compared to Other Atypical Antipsychotics Using the Korean Adverse Event Reporting System Database"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3750-7529","authenticated-orcid":false,"given":"Dong-Eun","family":"Seo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4993-7537","authenticated-orcid":false,"given":"Seonji","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4630-4942","authenticated-orcid":false,"given":"Byung-Joo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,9]]},"reference":[{"key":"945_CR1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2147\/CEOR.S156308","volume":"10","author":"W Zhang","year":"2018","unstructured":"Zhang W, Amos TB, Gutkin SW, Lodowski N, Giegerich E, Joshi K. A systematic literature review of the clinical and health economic burden of schizophrenia in privately insured patients in the United States. Clinicoecon Outcomes Res. 2018;10:309.","journal-title":"Clinicoecon Outcomes Res."},{"key":"945_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/ppc.12332","author":"SJ Kang","year":"2018","unstructured":"Kang SJ, Ko SH, Kim JY, Kim SR. Effects of a mental fitness positive psychology intervention program on inpatients with schizophrenia in South Korea: a feasibility study. Perspect Psychiatr Care. 2018. https:\/\/doi.org\/10.1111\/ppc.12332.","journal-title":"Perspect Psychiatr Care."},{"key":"945_CR3","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/schbul\/sby058","volume":"44","author":"FJ Charlson","year":"2018","unstructured":"Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull. 2018;44:1195\u2013203.","journal-title":"Schizophr Bull."},{"key":"945_CR4","first-page":"1989","volume":"11","author":"C-F Chiou","year":"2015","unstructured":"Chiou C-F, Wang BC, Caldwell R, Furnback W, Lee J-S, Kothandaraman N, et al. The cost reduction in hospitalization associated with paliperidone palmitate in the People\u2019s Republic of China, Korea, and Malaysia. Neuropsychiatr Dis Treat. 2015;11:1989.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"945_CR5","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3346\/jkms.2017.32.5.835","volume":"32","author":"W Kim","year":"2017","unstructured":"Kim W, Jang SY, Chun SY, Lee TH, Han KT, Park EC. Mortality in schizophrenia and other psychoses: data from the South Korea National Health Insurance Cohort, 2002\u20132013. J Korean Med Sci. 2017;32:835\u201342. https:\/\/doi.org\/10.3346\/jkms.2017.32.5.835.","journal-title":"J Korean Med Sci."},{"key":"945_CR6","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s12272-013-0105-7","volume":"36","author":"EJ Park","year":"2013","unstructured":"Park EJ, Amatya S, Kim MS, Park JH, Seol E, Lee H, et al. Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia. Arch Pharm Res. 2013;36:651\u20139.","journal-title":"Arch Pharm Res."},{"key":"945_CR7","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1080\/24750573.2017.1387404","volume":"28","author":"\u00c7 Yekta\u015f","year":"2018","unstructured":"Yekta\u015f \u00c7, Pa\u015fabeyo\u011flu B, Mutlu C, Erdo\u011fan A. The prescribing pattern of paliperidone in a pediatric population. Psychiatry Clin Psychopharmacol. 2018;28:156\u201362.","journal-title":"Psychiatry Clin Psychopharmacol."},{"key":"945_CR8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/schbul\/sbn015","volume":"34","author":"AM Nussbaum","year":"2008","unstructured":"Nussbaum AM, Stroup TS. Paliperidone for treatment of schizophrenia. Schizophr Bull. 2008;34:419\u201322.","journal-title":"Schizophr Bull."},{"key":"945_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2146\/ajhp070261","volume":"65","author":"C Dolder","year":"2008","unstructured":"Dolder C, Nelson M, Deyo Z. Paliperidone for schizophrenia. Am J Health Syst Pharm. 2008;65:403\u201313.","journal-title":"Am J Health Syst Pharm."},{"key":"945_CR10","doi-asserted-by":"publisher","first-page":"531","DOI":"10.9758\/cpn.2019.17.4.531","volume":"17","author":"S-Y Oh","year":"2019","unstructured":"Oh S-Y, Jon D-I, Hong HJ, Hong N, Yi J-S, Roh D, et al. The impact of paliperidone palmitate on hospitalization in patients with schizophrenia: a retrospective mirror-image study. Clin Psychopharmacol Neurosci. 2019;17:531.","journal-title":"Clin Psychopharmacol Neurosci."},{"key":"945_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4306\/jknpa.2015.54.1.69","volume":"54","author":"H Kim","year":"2015","unstructured":"Kim H, Lee J, Kim C, Joo Y. The drug adherence and treatment effect of the paliperidone long acting injection. J Korean Neuropsychiatr Assoc. 2015;54:69\u201375.","journal-title":"J Korean Neuropsychiatr Assoc."},{"key":"945_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/JCP.0000000000000046","volume":"34","author":"H-J Chen","year":"2014","unstructured":"Chen H-J, Lin S-T, Hsu H-C, Cheng K-D, Tsang H-Y. Paliperidone-related peripheral edema: a case report and review of the literature. J Clin Psychopharmacol. 2014;34:269\u201371.","journal-title":"J Clin Psychopharmacol."},{"key":"945_CR13","doi-asserted-by":"publisher","first-page":"E51","DOI":"10.1176\/appi.neuropsych.12050119","volume":"25","author":"B Havaki-Kontaxaki","year":"2013","unstructured":"Havaki-Kontaxaki B, Karaiskos D, Pappa D, Papadimitriou GN. Paliperidone-induced tardive dystonia: a case report. J Neuropsychiatry Clin Neurosci. 2013;25:E51.","journal-title":"J Neuropsychiatry Clin Neurosci."},{"key":"945_CR14","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1080\/03007995.2016.1198755","volume":"32","author":"P Pierce","year":"2016","unstructured":"Pierce P, Gopal S, Savitz A, Qiu H, Hino T, Busch M, et al. Paliperidone palmitate: Japanese postmarketing mortality results in patients with schizophrenia. Curr Med Res Opin. 2016;32:1671\u20139.","journal-title":"Curr Med Res Opin."},{"issue":"4","key":"945_CR15","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/JCP.0000000000001059","volume":"39","author":"S Kim","year":"2019","unstructured":"Kim S, Ko Y-J, Park K, Yang BR, Kim M-S, Park B-J. Fluoxetine and risk of bleeding in patients aged 60 years and older using the Korea adverse event reporting system database: a case\/noncase study. J Clin Psychopharmacol. 2019;39(4):362\u20136.","journal-title":"J Clin Psychopharmacol"},{"key":"945_CR16","doi-asserted-by":"publisher","first-page":"205427041875857","DOI":"10.1177\/2054270418758570","volume":"9","author":"R Roberts","year":"2018","unstructured":"Roberts R, Neasham A, Lambrinudi C, Khan A. A quantitative analysis of antipsychotic prescribing trends for the treatment of schizophrenia in England and Wales. JRSM Open. 2018;9:2054270418758570. https:\/\/doi.org\/10.1177\/2054270418758570.","journal-title":"JRSM Open."},{"key":"945_CR17","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/pds.1323","volume":"16","author":"WP Stephenson","year":"2007","unstructured":"Stephenson WP, Hauben M. Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf. 2007;16:359\u201365. https:\/\/doi.org\/10.1002\/pds.1323.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"945_CR18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.psychres.2017.06.038","volume":"256","author":"S Kim","year":"2017","unstructured":"Kim S, Park K, Kim M-S, Yang BR, Choi HJ, Park B-J. Data-mining for detecting signals of adverse drug reactions of fluoxetine using the Korea Adverse Event Reporting System (KAERS) database. Psychiatry Res. 2017;256:237\u201342.","journal-title":"Psychiatry Res"},{"key":"945_CR19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"S Evans","year":"2001","unstructured":"Evans S, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10:483\u20136.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"945_CR20","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13:519\u201323.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"945_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54:315\u201321.","journal-title":"Eur J Clin Pharmacol."},{"key":"945_CR22","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.3346\/jkms.2016.31.9.1355","volume":"31","author":"M Soukavong","year":"2016","unstructured":"Soukavong M, Kim J, Park K, Yang BR, Lee J, Jin X-M, et al. Signal detection of adverse drug reaction of amoxicillin using the Korea Adverse Event Reporting System Database. J Korean Med Sci. 2016;31:1355\u201361.","journal-title":"J Korean Med Sci."},{"key":"945_CR23","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/YIC.0b013e3281c55f4f","volume":"22","author":"R Luthringer","year":"2007","unstructured":"Luthringer R, Staner L, Noel N, Muzet M, Gassmann-Mayer C, Talluri K, et al. A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. Int Clin Psychopharmacol. 2007;22:299\u2013308. https:\/\/doi.org\/10.1097\/YIC.0b013e3281c55f4f.","journal-title":"Int Clin Psychopharmacol."},{"key":"945_CR24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jpsychires.2004.08.002","volume":"39","author":"RG McCreadie","year":"2005","unstructured":"McCreadie RG, Srinivasan TN, Padmavati R, Thara R. Extrapyramidal symptoms in unmedicated schizophrenia. J Psychiatr Res. 2005;39:261\u20136.","journal-title":"J Psychiatr Res."},{"key":"945_CR25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.schres.2006.09.012","volume":"90","author":"J Kane","year":"2007","unstructured":"Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007;90:147\u201361.","journal-title":"Schizophr Res."},{"key":"945_CR26","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.2147\/NDT.S49944","volume":"9","author":"S Gopal","year":"2013","unstructured":"Gopal S, Liu Y, Alphs L, Savitz A, Nuamah I, Hough D. Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a post-hoc pooled analysis of seven randomized controlled studies. Neuropsychiatr Dis Treat. 2013;9:1381\u201392. https:\/\/doi.org\/10.2147\/NDT.S49944.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"945_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000339456","volume":"66","author":"S Walther","year":"2012","unstructured":"Walther S, Strik W. Motor symptoms and schizophrenia. Neuropsychobiology. 2012;66:77\u201392.","journal-title":"Neuropsychobiology."},{"key":"945_CR28","first-page":"252","volume":"29","author":"P Celada","year":"2004","unstructured":"Celada P, Puig MV, Amarg\u00f3s-Bosch M, Adell A, Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci. 2004;29:252.","journal-title":"J Psychiatry Neurosci."},{"key":"945_CR29","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/phar.1313","volume":"33","author":"S Gentile","year":"2013","unstructured":"Gentile S. Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review. Pharmacotherapy. 2013;33:1087\u2013106.","journal-title":"Pharmacotherapy."},{"key":"945_CR30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/0269881107088439","volume":"22","author":"V O\u2019Keane","year":"2008","unstructured":"O\u2019Keane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol. 2008;22:70\u20135.","journal-title":"J Psychopharmacol."},{"key":"945_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000010154","volume":"48","author":"RA Nowak","year":"1999","unstructured":"Nowak RA, Mora S, Diehl T, Rhoades A, Stewart EA. Prolactin is an autocrine or paracrine growth factor for human myometrial and leiomyoma cells. Gynecol Obstet Investig. 1999;48:127\u201332.","journal-title":"Gynecol Obstet Investig."},{"key":"945_CR32","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.pnpbp.2012.06.024","volume":"39","author":"K-S Na","year":"2012","unstructured":"Na K-S, Kim W-H, Jung H-Y, Ryu SG, Min KJ, Park K-C, et al. Relationship between inflammation and metabolic syndrome following treatment with paliperidone for schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39:295\u2013300.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"945_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00213-013-3073-1","volume":"230","author":"S Hu","year":"2013","unstructured":"Hu S, Yao M, Peterson BS, Xu D, Hu J, Tang J, et al. A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and \u03b2-cell function in schizophrenic patients. Psychopharmacology. 2013;230:3\u201313.","journal-title":"Psychopharmacology."},{"key":"945_CR34","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3389\/fpsyt.2018.00622","volume":"9","author":"NE MacKenzie","year":"2018","unstructured":"MacKenzie NE, Kowalchuk C, Agarwal SM, Costa-Dookhan KA, Caravaggio F, Gerretsen P, et al. Antipsychotics, metabolic adverse effects, and cognitive function in schizophrenia. Front Psychiatry. 2018;9:622. https:\/\/doi.org\/10.3389\/fpsyt.2018.00622.","journal-title":"Front Psychiatry."},{"key":"945_CR35","first-page":"158","volume":"14","author":"M Bhatia","year":"2011","unstructured":"Bhatia M, Jhanjee A, Srivastava S, Kumar P. Paliperidone induced exanthematous rash. Delhi Psychiatry J. 2011;14:158\u20139.","journal-title":"Delhi Psychiatry J."},{"key":"945_CR36","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jad.2017.07.037","volume":"223","author":"N Cockburn","year":"2017","unstructured":"Cockburn N, Pradhan A, Taing M, Kisely S, Ford P. Oral health impacts of medications used to treat mental illness. J Affect Disord. 2017;223:184\u201393.","journal-title":"J Affect Disord."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00945-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-020-00945-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00945-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T23:23:30Z","timestamp":1625786610000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-020-00945-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,9]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["945"],"URL":"https:\/\/doi.org\/10.1007\/s40261-020-00945-z","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"type":"print","value":"1173-2563"},{"type":"electronic","value":"1179-1918"}],"subject":[],"published":{"date-parts":[[2020,7,9]]},"assertion":[{"value":"9 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No funding support was received for this research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The study was exempted from review by the institutional review board of Seoul National University College of Medicine (IRB No. 1911-051-1078) because it used secondary healthcare data, which did not contain any personally identifiable information, and receiving informed consent from patients was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}